12:00 AM
 | 
Mar 20, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

UFT tegafur/uracil capsules regulatory update

BMY withdrew its NDA for UFT as a first-line treatment for advanced colorectal cancer in combination with leucovorin, and also...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >